TriangleHEALTH PROFESSIONAL · SOURCE READING
Lenvatinib
Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: October 25, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Lenvatinib is an orally administered multikinase inhibitor that targets vascular endothelial growth factor receptors, platelet-derived growth factor receptor-alpha, fibroblast growth factor receptors, c-kit, and the RET proto-oncogene.
Evidence (lenvatinib):
Forty-two patients with recurrent thymic carcinoma were enrolled in a phase II trial and treated with oral lenvatinib at a dose of 24 mg per day in 4-week cycles until disease progression or development of unacceptable adverse events. The primary end point was objective response rate, assessed by independent central review.[8][Level of evidence C3]
Source links and citations
Forty-two patients with recurrent thymic carcinoma were enrolled in a phase II trial and treated with oral lenvatinib at a dose of 24 mg per day in 4-week cycles until disease progression or development of unacceptable adverse events. The primary end point was objective response rate, assessed by independent central review.[8][Level of evidence C3]
Objective responses were observed in 16 of 42 patients (38%; 90% CI, 25.6%–52.0%).
Forty-two patients with recurrent thymic carcinoma were enrolled in a phase II trial and treated with oral lenvatinib at a dose of 24 mg per day in 4-week cycles until disease progression or development of unacceptable adverse events. The primary end point was objective response rate, assessed by independent central review.[8][Level of evidence C3]
The disease-control rate was 95% (95% CI, 83.8%–99.4%).
Forty-two patients with recurrent thymic carcinoma were enrolled in a phase II trial and treated with oral lenvatinib at a dose of 24 mg per day in 4-week cycles until disease progression or development of unacceptable adverse events. The primary end point was objective response rate, assessed by independent central review.[8][Level of evidence C3]
After a median follow-up of 15.5 months, the median time to response was 2.0 months, the median duration of response was 11.6 months (95% CI, 5.8–18.0), the median PFS was 9.3 months (95% CI, 7.7–13.9), and the median OS was not reached (NR) (95% CI, 16.1–NR).
Forty-two patients with recurrent thymic carcinoma were enrolled in a phase II trial and treated with oral lenvatinib at a dose of 24 mg per day in 4-week cycles until disease progression or development of unacceptable adverse events. The primary end point was objective response rate, assessed by independent central review.[8][Level of evidence C3]
The most common treatment-related adverse events were hypertension (88%), palmar-plantar erythrodysesthesia (69%), thrombocytopenia (52%), and diarrhea (50%).
Forty-two patients with recurrent thymic carcinoma were enrolled in a phase II trial and treated with oral lenvatinib at a dose of 24 mg per day in 4-week cycles until disease progression or development of unacceptable adverse events. The primary end point was objective response rate, assessed by independent central review.[8][Level of evidence C3]
All patients required at least one dose reduction due to adverse events. Five dose reductions were permitted in this study (20 mg, 14 mg, 10 mg, 8 mg, 4 mg). There were no treatment-related deaths.
Forty-two patients with recurrent thymic carcinoma were enrolled in a phase II trial and treated with oral lenvatinib at a dose of 24 mg per day in 4-week cycles until disease progression or development of unacceptable adverse events. The primary end point was objective response rate, assessed by independent central review.[8][Level of evidence C3]
Predictive biomarker analysis was not performed as part of this clinical trial.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice